Skip to main content
Top
Published in: Hepatology International 6/2016

01-11-2016 | Original Article

Serial measurement of Wisteria floribunda agglutinin positive Mac-2-binding protein is useful for predicting liver fibrosis and the development of hepatocellular carcinoma in chronic hepatitis C patients treated with IFN-based and IFN-free therapy

Authors: Hiroko Nagata, Mina Nakagawa, Yuki Nishimura-Sakurai, Yu Asano, Tomoyuki Tsunoda, Masato Miyoshi, Shun Kaneko, Fumio Goto, Satoshi Otani, Fukiko Kawai-Kitahata, Miyako Murakawa, Sayuri Nitta, Yasuhiro Itsui, Seishin Azuma, Sei Kakinuma, Naoko Tojo, Shuji Tohda, Yasuhiro Asahina, Mamoru Watanabe, The Ochanomizu Liver Conference Study Group

Published in: Hepatology International | Issue 6/2016

Login to get access

Abstract

Aim

Wisteria floribunda agglutinin positive (WFA+) Mac-2-binding protein (M2BPGi) is a noninvasive glyco-marker for liver fibrosis. This study evaluated the utility of serial measurement of serum M2BPGi and total M2BP as a predictor of fibrosis and the development of hepatocellular carcinoma (HCC).

Methods

This study included 119 patients with chronic hepatitis C (CHC). Of these patients, 97 were treated with IFN-based therapy and 22 were treated with daclatasvir and asunaprevir. Serum M2BPGi values were measured prior to, at the end of, and at 24 weeks after the completion of treatment. As subanalysis, serum total M2BP levels were measured in patients treated with pegylated-interferon and ribavirin.

Results

In patients treated with IFN-based therapy, M2BPGi levels were elevated at the end of treatment but decreased afterwards. In contrast, M2BPGi levels in patients treated with IFN-free therapy decreased immediately after starting the treatment without transient elevation. Though pre-treatment M2BPGi levels significantly correlated with fibrosis in both patients with a sustained virological response (SVR) and non-SVR, post-treatment M2BPGi levels decreased regardless of the degree of fibrosis in patients with SVR. In multivariate analysis, non-SVR and HCC development were independent factors associated with M2BPGi level ≥2.2. In patients treated with pegylated-interferon and ribavirin, total M2BP levels were positively correlated with fibrosis and HCC development.

Conclusion

Real-time monitoring of the serum M2BPGi level after antiviral therapy for CHC patients could be a helpful screening tool for assessing the risk of HCC. M2BP and its glycan structure could be associated together with hepatocarcinogenesis.
Appendix
Available only for authorised users
Literature
1.
go back to reference Forner A, et al. Hepatocellular carcinoma. Lancet 2012;379:1245–1255 Forner A, et al. Hepatocellular carcinoma. Lancet 2012;379:1245–1255
2.
go back to reference Mohd Hanafiah K, et al. Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence. Hepatology 2013;57:1333–1342 Mohd Hanafiah K, et al. Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence. Hepatology 2013;57:1333–1342
3.
go back to reference Asahina Y, et al. Effect of aging on risk for hepatocellular carcinoma in chronic hepatitis C virus infection. Hepatology 2010;52:518–527 Asahina Y, et al. Effect of aging on risk for hepatocellular carcinoma in chronic hepatitis C virus infection. Hepatology 2010;52:518–527
4.
go back to reference Asahina Y, et al. α-Fetoprotein levels after interferon therapy and risk of hepatocarcinogenesis in chronic hepatitis C. Hepatology 2013;58:1253–1262 Asahina Y, et al. α-Fetoprotein levels after interferon therapy and risk of hepatocarcinogenesis in chronic hepatitis C. Hepatology 2013;58:1253–1262
5.
go back to reference Kuno A, et al. A serum “sweet-doughnut” protein facilitates fibrosis evaluation and therapy assessment in patients with viral hepatitis. Sci Rep 2013;3:1065 Kuno A, et al. A serum “sweet-doughnut” protein facilitates fibrosis evaluation and therapy assessment in patients with viral hepatitis. Sci Rep 2013;3:1065
6.
go back to reference Kuno A, et al. Reconstruction of a robust glycodiagnostic agent supported by multiple lectin-assisted glycan profiling. Proteom Clin Appl 2013;7:642–647 Kuno A, et al. Reconstruction of a robust glycodiagnostic agent supported by multiple lectin-assisted glycan profiling. Proteom Clin Appl 2013;7:642–647
7.
go back to reference Fujiyoshi M, et al. Hepatitis Glyco-biomarker study group. Clinicopathological characteristics and diagnostic performance of Wisteria floribunda agglutinin positive Mac-2-binding protein as a preoperative serum marker of liver fibrosis in hepatocellular carcinoma. J Gastroenterol 2015;50:1134–1144 Fujiyoshi M, et al. Hepatitis Glyco-biomarker study group. Clinicopathological characteristics and diagnostic performance of Wisteria floribunda agglutinin positive Mac-2-binding protein as a preoperative serum marker of liver fibrosis in hepatocellular carcinoma. J Gastroenterol 2015;50:1134–1144
8.
go back to reference Tamaki N, et al. Wisteria floribunda agglutinin positive human Mac-2-binding protein as a predictor of hepatocellular carcinoma development in chronic hepatitis C patients. Hepatol Res 2015;45:E82–88 Tamaki N, et al. Wisteria floribunda agglutinin positive human Mac-2-binding protein as a predictor of hepatocellular carcinoma development in chronic hepatitis C patients. Hepatol Res 2015;45:E82–88
9.
go back to reference Hanai T, et al. Impact of serum glycosylated Wisteria floribunda agglutinin-positive Mac-2-binding protein levels on liver functional reserves and mortality in patients with liver cirrhosis. Hepatol Res 2015;45:1083–1090 Hanai T, et al. Impact of serum glycosylated Wisteria floribunda agglutinin-positive Mac-2-binding protein levels on liver functional reserves and mortality in patients with liver cirrhosis. Hepatol Res 2015;45:1083–1090
10.
go back to reference Sasaki R, et al. Serum Wisteria Floribunda agglutinin-positive Mac-2-binding protein values predict the development of hepatocellular carcinoma among patients with chronic hepatitis C after sustained virological response. PLoS One 2015;10:e0129053 Sasaki R, et al. Serum Wisteria Floribunda agglutinin-positive Mac-2-binding protein values predict the development of hepatocellular carcinoma among patients with chronic hepatitis C after sustained virological response. PLoS One 2015;10:e0129053
11.
go back to reference Wai CT, et al. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology 2003;38:518–26 Wai CT, et al. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology 2003;38:518–26
12.
go back to reference Sterling RK, et al. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology 2006;43:1317–1325 Sterling RK, et al. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology 2006;43:1317–1325
13.
go back to reference Desmet VJ, et al. Classification of chronic hepatitis: diagnosis, grading and staging. Hepatology 1994;19:1513–1520 Desmet VJ, et al. Classification of chronic hepatitis: diagnosis, grading and staging. Hepatology 1994;19:1513–1520
14.
go back to reference Artini M, et al. Elevated serum levels of 90 K/MAC-2 BP predict unresponsiveness to alpha-interferon therapy in chronic HCV hepatitis patients. J Hepatol 1996;25:212–217 Artini M, et al. Elevated serum levels of 90 K/MAC-2 BP predict unresponsiveness to alpha-interferon therapy in chronic HCV hepatitis patients. J Hepatol 1996;25:212–217
15.
go back to reference Cheung KJ, et al. The HCV serum proteome: a search for fibrosis protein markers. J Viral Hepat 2009;16:418–429 Cheung KJ, et al. The HCV serum proteome: a search for fibrosis protein markers. J Viral Hepat 2009;16:418–429
16.
go back to reference Yamasaki K, et al. Elevated serum levels of Wisteria floribunda agglutinin-positive human Mac-2-binding protein predict the development of hepatocellular carcinoma in hepatitis C patients. Hepatology 2014;60:1563–1570 Yamasaki K, et al. Elevated serum levels of Wisteria floribunda agglutinin-positive human Mac-2-binding protein predict the development of hepatocellular carcinoma in hepatitis C patients. Hepatology 2014;60:1563–1570
17.
go back to reference Ura k, et al. Serum WFA(+)-M2BP is a non-invasive liver fibrosis marker that can predict the efficacy of direct-acting anti-viral-based triple therapy for chronic hepatitis C. Aliment Pharmacol Ther 2016;43:114–124 Ura k, et al. Serum WFA(+)-M2BP is a non-invasive liver fibrosis marker that can predict the efficacy of direct-acting anti-viral-based triple therapy for chronic hepatitis C. Aliment Pharmacol Ther 2016;43:114–124
18.
go back to reference Abe M, et al. Association between Wisteria floribunda agglutinin-positive Mac-2-binding protein and the fibrosis stage of non-alcoholic fatty liver disease. J Gastroenterol 2015;50:776–784 Abe M, et al. Association between Wisteria floribunda agglutinin-positive Mac-2-binding protein and the fibrosis stage of non-alcoholic fatty liver disease. J Gastroenterol 2015;50:776–784
19.
go back to reference Marcello T, et al. Interferons alpha and lambda inhibit hepatitis C virus replication with distinct signal transduction and gene regulation kinetics. Gastroenterology 2006;13:1887–1898 Marcello T, et al. Interferons alpha and lambda inhibit hepatitis C virus replication with distinct signal transduction and gene regulation kinetics. Gastroenterology 2006;13:1887–1898
20.
go back to reference Shirure VS, et al. Mac-2-binding protein is a novel E-selectin ligand expressed by breast cancer cells. PLoS One 2012;7:e44529 Shirure VS, et al. Mac-2-binding protein is a novel E-selectin ligand expressed by breast cancer cells. PLoS One 2012;7:e44529
21.
go back to reference Hu J, et al. Expression and significance of 90 K/Mac-2BP in prostate cancer. Exp Ther Med 2013;5:181–184 Hu J, et al. Expression and significance of 90 K/Mac-2BP in prostate cancer. Exp Ther Med 2013;5:181–184
22.
go back to reference Sun L, et al. Functional screen for secreted proteins by monoclonal antibody library and identification of Mac-2-binding protein (Mac-2BP) as a potential therapeutic target and biomarker for lung cancer. Mol Cell Proteom 2013;12:395–406 Sun L, et al. Functional screen for secreted proteins by monoclonal antibody library and identification of Mac-2-binding protein (Mac-2BP) as a potential therapeutic target and biomarker for lung cancer. Mol Cell Proteom 2013;12:395–406
23.
go back to reference Vásquez-Garzón VR, et al. Analysis of gene expression profiles as a tool to uncover tumor markers of liver cancer progression in a rat model. Biomed Rep 2015;3:167–172 Vásquez-Garzón VR, et al. Analysis of gene expression profiles as a tool to uncover tumor markers of liver cancer progression in a rat model. Biomed Rep 2015;3:167–172
24.
go back to reference Tawara S, et al. Evaluation of fucosylated haptoglobin and Mac-2-binding protein as serum biomarkers to estimate liver fibrosis in patients with chronic hepatitis C. PLoS One 2016;11:e0151828 Tawara S, et al. Evaluation of fucosylated haptoglobin and Mac-2-binding protein as serum biomarkers to estimate liver fibrosis in patients with chronic hepatitis C. PLoS One 2016;11:e0151828
Metadata
Title
Serial measurement of Wisteria floribunda agglutinin positive Mac-2-binding protein is useful for predicting liver fibrosis and the development of hepatocellular carcinoma in chronic hepatitis C patients treated with IFN-based and IFN-free therapy
Authors
Hiroko Nagata
Mina Nakagawa
Yuki Nishimura-Sakurai
Yu Asano
Tomoyuki Tsunoda
Masato Miyoshi
Shun Kaneko
Fumio Goto
Satoshi Otani
Fukiko Kawai-Kitahata
Miyako Murakawa
Sayuri Nitta
Yasuhiro Itsui
Seishin Azuma
Sei Kakinuma
Naoko Tojo
Shuji Tohda
Yasuhiro Asahina
Mamoru Watanabe
The Ochanomizu Liver Conference Study Group
Publication date
01-11-2016
Publisher
Springer India
Published in
Hepatology International / Issue 6/2016
Print ISSN: 1936-0533
Electronic ISSN: 1936-0541
DOI
https://doi.org/10.1007/s12072-016-9754-1

Other articles of this Issue 6/2016

Hepatology International 6/2016 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine